Psoriasis

Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis

LONG BEACH, Calif., and BASEL, Switzerland, August 26, 2020—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream, …

Read More »

FDA Approves Stelara for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

HORSHAM, Pa., July 30, 2020  — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) who struggle with the skin lesions or plaques associated with moderate to …

Read More »

Bimekizumab Superior to Cosentyx in Achieving Complete Psoriasis Skin Clearance in Phase 3 Study

BRUSSELS, July 24, 2020 /PRNewswire/ — Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3b BE RADIANT study, a direct comparison of the investigational IL-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Cosentyx® (secukinumab) in the treatment of adult …

Read More »

Lilly’s Mirikizumab Superior to Cosentyx in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

INDIANAPOLIS, July 17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week …

Read More »

FDA Approves Tremfya, the First Selective Interleukin-23 Inhibitor for Treatment of Active Psoriatic Arthritis

HORSHAM, Pa., July 14, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 TREMFYA is the first treatment approved for active …

Read More »

Mylan and Fujifilm Kyowa Kirin Biologics Announce that the FDA Approved of Hulio, a Biosimilar to Humira

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie’s Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic …

Read More »

Galderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental Wellbeing

LAUSANNE, Switzerland, June 10, 2020 /PRNewswire/ — A new expert-authored Galderma report released today reveals the true extent of the hidden burden of rosacea and psoriasis of the face on patients’ lives. Findings of this global survey – Beyond the visible: rosacea and psoriasis of the face – show that …

Read More »

Amgen Announces Positive Top-Line Results from Phase 3 Study of Otezla in Patients with Mild-to-Moderate Plaque Psoriasis

THOUSAND OAKS, Calif., May 6, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with mild-to-moderate plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a statistically significant improvement, compared …

Read More »

FDA Approves Lilly’s Taltz for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

INDIANAPOLIS, March 30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic …

Read More »

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed …

Read More »